Heart failure & cardiomyopathies
Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction
Authors' conclusion
New statin use was associated with reduced all-cause mortality, MACE, and hospitalization in Veterans with HFpEF without prevalent ASCVD.
Study context
- Population
- Veterans with new heart failure with preserved ejection fraction (HFpEF) diagnosis, no known atherosclerotic cardiovascular disease (ASCVD) or prior statin use, Veterans Health Administration data 2002–201647% initiated a statin
- Participants
- 7,970 veterans
- Exposure
- New statin use vs no statin
- Outcome
- All-cause mortality and MACE
- Follow-up
- mean 6.0-year follow-up
Methodological detailspropensity score overlap weighting
- Propensity score overlap weighting
Main finding
As reported in the abstract
Statin users vs NonusersHazard ratio (95% CI)
All-cause mortality
0.78(0.73–0.83)
MACE
0.79(0.74–0.84)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause hospitalization | 0.69 (0.60–0.80) | |
| HF hospitalization | 0.72 (0.59–0.88) | |
| 0.512Hazard ratio (log scale) |
Original publication
Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction. JACC Adv. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →